Belfast, Northern Ireland, 24/06/2025

Sonrai Analytics (Sonrai), a leader in AI precision medicine, and Plectonic Biotech (Plectonic), a German biotechnology company, today announced a collaboration to accelerate the development of Plectonic’s LOGIBODY® (logic-gated antibody) immunotherapy technology across multiple cancer types. As part of the project, Sonrai will apply its advanced AI technology and bioinformatics expertise to identify and validate ultra-specific antigen combinations to guide Plectonic’s tumor-targeting while minimizing impact on healthy cells. This synergy aims to fast-track the development of the LOGIBODY® platform by combining Sonrai’s cutting-edge data science with Plectonic’s breakthrough DNA nanotechnology. 

Using Sonrai’s AI-driven, multi-modal approach, which integrates single-cell RNA sequencing with proteomic mass spectrometry datasets, the study will quantitatively assess antigen co-expression patterns in tumor versus healthy tissues, in both solid and blood cancer indications. This high-resolution approach, powered by Sonrai’s cloud-based advanced analytics platform and integrated bioinformatics pipelines, enables scalable, multi-omics analysis to accelerate target discovery and validation workflows.

At the core of the project is Plectonic’s proprietary LOGIBODY® technology – a logic-gated antibody platform that acts as a molecular switch, triggering an antibody-mediated immune response only in the presence of specific tumor antigens. This approach aims to maximize treatment precision while minimizing toxicity, thereby lowering side effects for patients.

“This project demonstrates the power of AI and multi-modal analysis to tackle complex biomedical challenges, accelerating the development of next-generation immunotherapies.” said Prof. Darragh McArt, CEO and Founder, Sonrai. “We’re honored to support Plectonic as they advance their groundbreaking immunotherapy technology, reflecting our mission to bring safer, more effective cancer treatments to patients.” 

“Working with Sonrai represents a crucial step in validating and refining our LOGIBODY® technology across a range of cancer types. By leveraging Sonrai’s AI platform, we will be able to identify the most promising therapeutic targets and accelerate our path to clinical trials,” said Dr. Klaus Wagenbauer, CEO and Founder, Plectonic Biotech. “This brings us closer to delivering therapies that offer hope to cancer patients while dramatically reducing the burden of treatment-induced side effects.”

About Sonrai Analytics

Sonrai Analytics, founded in 2018, is an AI precision medicine technology company. Sonrai’s flagship product, Sonrai Discovery, expedites identifying and developing drug or therapeutic targets, improving patient outcomes through AI. The company partners with biotechnology and pharmaceutical companies to manage and analyze their precision medicine data. By leveraging Sonrai Discovery, these companies can confidently select compounds with the highest potential for success in clinical trials, accelerating drug development and mitigating the risk of failures during human trials.

For additional information about Sonrai, please visit: sonraianalytics.com. 

About Plectonic Biotech

Plectonic Biotech, based near Munich, Germany, is a biotech startup developing next-generation immunotherapies using its proprietary LOGIBODY® platform. Spun out of the Technical University of Munich in 2022, the company leverages DNA nanotechnology to create logic-gated antibody systems – ultra-miniaturized nanoswitches that activate immune responses only when cancer-specific markers are detected. This precision approach reduces off-target toxicity and improves therapeutic efficacy, addressing a significant limitation of conventional antibody-based therapies. 

Backed by Germany’s Federal Agency for Disruptive Innovation (SPRIND), Plectonic is advancing its lead candidates through preclinical development and into clinical trials, with initial focus on oncology.